Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

• If you are wondering whether Amylyx Pharmaceuticals at US$14.73 is still offering value after a strong run, it helps to step back and look at what the price is really reflecting.
• The stock is up 29.0% year to date and 220.2% over the past year, even though it has fallen about 10.5% over the past week and 10.0% over the past month. These moves can change how you think about both opportunity and risk.
• Across financial media and industry commentary, recent attention has focused on Amylyx as a higher profile biotech stock. Investors have been reacting to company specific updates and shifting sentiment around its drug pipeline and regulatory path. These developments help explain why the share price has moved sharply in both directions over different timeframes.
• Right now Amylyx scores 2 out of 6 on a simple valuation checklist. The next sections will walk through what different valuation approaches say about the stock and then finish with a more complete way to think about what that score really means.

Amylyx Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Amylyx Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today’s dollars, aiming to show what the business could be worth based on those projected cash streams.

For Amylyx Pharmaceuticals, the model used is a 2 stage Free Cash Flow to Equity approach. The company is currently reporting last twelve month free cash flow of a loss of $120.53 million. Analyst and model projections suggest that free cash flow stays in loss territory for several years, then turns positive, reaching a projected $76.53 million in 2030. Estimates beyond the initial analyst horizon are extrapolated by Simply Wall St, so they should be treated as more uncertain than the nearer term numbers.

On this basis, the DCF approach points to an estimated intrinsic value of about $48.59 per share. Compared with the recent share price of $14.73, this output implies the stock is 69.7% undervalued according to this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amylyx Pharmaceuticals is undervalued by 69.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amylyx Pharmaceuticals.

Approach 2: Amylyx Pharmaceuticals Price vs Book

For companies where earnings can be volatile or still in loss territory, the P/B ratio is often a useful cross check because it anchors the valuation to the net assets on the balance sheet rather than current profits.

In general, the multiple investors are willing to pay over book value tends to reflect expectations for future growth and the level of business risk. Higher growth and lower perceived risk can support a higher P/B ratio, while slower growth or higher uncertainty usually point to a lower, more conservative multiple.

Amylyx currently trades on a P/B ratio of 5.99x. That sits above the broader Pharmaceuticals industry average of 2.70x and also above its peer group average of 3.57x. Simply Wall St’s Fair Ratio is a proprietary estimate of what a reasonable P/B might be for Amylyx, given factors such as its earnings profile, industry, profit margins, market value and company specific risks.

This Fair Ratio can be more informative than a simple comparison with peers or industry averages because it adjusts for Amylyx’s own growth outlook, risk profile, margins, sector and size, rather than assuming that all companies should trade on the same benchmark multiple.

Result: OVERVALUED

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Amylyx Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring that idea to life by letting you attach a clear story about Amylyx Pharmaceuticals to specific revenue, earnings and margin assumptions, then link those to a Fair Value that can be compared with the current share price.

On Simply Wall St’s Community page, Narratives are set up as easy templates that update automatically when new information like news or earnings is released. This means you can quickly see whether the story you believe in still justifies your Fair Value compared with where the stock trades today.

For Amylyx, one Narrative might point to a Fair Value around US$34.00 based on revenue of US$459.0 million and earnings of US$41.4 million by 2029 with a P/E of 130.6x. A more cautious Narrative might point to a Fair Value closer to US$19.00 based on revenue of US$46.5 million, earnings of US$9.3 million and a higher P/E of 337.4x. Comparing either of these Fair Values to the current price can help you decide whether the stock looks closer to a buy, a hold or a sell for your own view of the business.

Do you think there’s more to the story for Amylyx Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com